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Transient receptor potential ankyrin 1 
(TRPA1) is a ligand-gated membrane-bound 
cation channel. TRPA1 has been largely 
studied in neurons, where it mediates pain 
and neurogenic inflammation and acts 
as a chemosensor for harmful exogenous 
compounds.1 2 More recently, TRPA1 has 
been found to be activated also by endoge-
nous compounds formed in inflammatory 
conditions characteristic to arthritis, such as 
reactive oxygen and nitrogen species.3
We have recently discovered that TRPA1 
is functionally expressed in primary human 
osteoarthritic chondrocytes,4 where it 
upregulated the production of mediators 
related to arthritis: interleukin (IL)-6, pros-
taglandin E2 and matrix metalloproteinases 
1, 3 and 13.4 Furthermore, we showed in 
monosodium iodoacetate-induced experi-
mental arthritis that TRPA1 activation medi-
ates inflammation, cartilage degradation 
and pain.5 TRPA1 thus emerges as a novel 
factor associated with arthritis. Therefore, 
we investigated the effects of disease-mod-
ifying antirheumatic drugs methotrexate, 
sulfasalazine, hydroxychloroquine and 
aurothiomalate, glucocorticoid dexameth-
asone and non-steroidal anti-inflammatory 
drug ibuprofen on the expression of TRPA1 
in human chondrocytes.
Human T/C28a2 chondrocytes6 were 
cultured with the aforementioned drugs, 
along with IL-1β, which was recently found 
to upregulate TRPA1 expression in chon-
drocytes.4 Dexamethasone and aurothioma-
late inhibited TRPA1 mRNA expression in a 
dose-dependent manner (figure 1A), while 
methotrexate (10 µM), sulfasalazine (10 µM), 
hydroxychloroquine (10 µM) and ibuprofen 
(10 µM) had no effect. Dexamethasone 
and aurothiomalate also decreased TRPA1 
protein levels (figure 1C).
Next, we examined if the observed drug 
effects on TRPA1 expression levels are func-
tional, that is, if they are translated to changes 
in TRPA1-mediated calcium influx. In chon-
drocytes, which had been cultured in the 
presence of IL-1β, TRPA1-mediated calcium 
influx was increased; while that effect was 
reversed in cells which had been cultured with 
a combination of IL-1β and dexamethasone 
or aurothiomalate (figure 1D,E), confirming 
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Inflammatory arthritis
Key messages
What is already known about this subject?
 ► transient receptor potential ankyrin 1 (trpA1) is 
a membrane-associated cation channel primarily 
studied in sensory neurons, where it acts as a 
chemosensor of pungent compounds and mediates 
pain.
 ► trpA1 has recently emerged as a potential factor/
mediator in arthritis; we have shown trpA1 to 
mediate inflammatory and catabolic responses 
in primary human chondrocytes, as well as 
cartilage degradation, inflammation and pain in an 
experimental model of arthritis.
What does this study add?
 ► this study shows that anti-inflammatory drugs 
dexamethasone and aurothiomalate downregulate 
the expression of functional trpA1 in human 
chondrocytes.
How might this impact on clinical practice?
 ► these results show a previously unknown 
mechanism of action for dexamethasone and 
aurothiomalate via downregulation of trpA1, and 
thus provides a novel concept for the development 
of drugs for arthritis with analgesic and disease 
modifying properties.
group.bmj.com on October 9, 2017 - Published by http://rmdopen.bmj.com/Downloaded from 
2 Nummenmaa e, et al. RMD Open 2017;3:e000556. doi:10.1136/rmdopen-2017-000556
RMD Open
Figure 1 Dexamethasone and aurothiomalate inhibit TRPA1 expression in human chondrocytes. Human chondrocytes 
(primary human chondrocytes or T/C28a2 chondrocyte cell line) were cultured with IL-1β alone or in combination with the anti-
inflammatory compound dexamethasone or aurothiomalate, or with the selective NF-κB inhibitor PDTC at concentrations given 
in the figure. (A, B) For TRPA1 mRNA expression analysis, human T/C28a2 chondrocytes (A) were incubated for 6 hours and 
the experiments were carried out in quadruplicate; primary chondrocytes (B) were incubated for 24 hours and the experiments 
were carried out in duplicate and repeated with cells from six donor patients. Total RNA was extracted and TRPA1 mRNA 
levels were measured by quantitative RT-PCR (TaqMan Gene Expression Assay for human TRPA1, Hs00175798_m1), and the 
results were normalised against GAPDH mRNA levels. (C) For TRPA1 protein analysis human T/C28a2 chondrocytes were 
incubated for 24 hours after which proteins were extracted and immunoprecipitated with TRPA1 antibody (SAB2105082, 
Sigma-Aldrich), and TRPA1 was detected with Western blot (with primary antibody: NB110-40763, NovusBiologicals). The 
figure shows one representative blot of six independent experiments with similar results. (D, E) For Ca2+ influx analysis human 
T/C28a2 chondrocytes were incubated with IL-1β alone or in combination with dexamethasone or aurothiomalate for 24 hours. 
Thereafter, the cells were loaded with Fluo-3-AM and the TRPA1-mediated Ca2+ influx was measured by Victor3 multilabel 
counter at excitation/emission wavelengths of 485/535 nm at 1/s frequency. In the measurements, basal fluorescence was 
first recorded for 15 s and thereafter the selective TRPA1 agonist AITC was added and the measurements were continued 
for 30 s. The results were normalised against the background and expressed as a mean of eight measurements. In (E), AUC 
from 15 to 45 s was calculated. Results are expressed as mean+SEM, results in (A–C) are expressed as a percentage in 
comparison to IL-1β-treated samples which were set as 100%. Statistical significance of the results was calculated with 
one-way or repeated measures ANOVA followed by Bonferroni post-test. Data were analysed using GraphPad InStat V.3.0. 
***p<0.001. AITC, allyl isothiocyanate; ANOVA, analysis of variance; AUC, area under the curve; GAPDH, glyceraldehyde-
3-phosphate dehydrogenase; IL, interleukin; NF-κB, nuclear factor kappa B; OA, osteoarthritic; PDTC, ammonium 
pyrrolidinedithiocarbamate; RT-PCR, reverse transcription PCR; TRPA1, transient receptor potential ankyrin 1.
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the functional downregulation of TRPA1 expression by 
these two drugs.
To confirm the effects of dexamethasone and 
aurothiomalate in primary human chondrocytes, cells 
were isolated from cartilage samples obtained from joint 
replacement surgery and cultured as described previ-
ously.4 Dexamethasone and aurothiomalate downreg-
ulated IL-1β-induced TRPA1 expression also in these 
primary chondrocytes (figure 1B).
The current results show for the first time that two 
anti-inflammatory drugs which are effective in the 
treatment of arthritis and retard cartilage degradation, 
namely dexamethasone and aurothiomalate, down-
regulate the expression of TRPA1 in human chondro-
cytes. Notably, inhibition of the transcription factor 
nuclear factor kappa B (NF-κB) also downregulated 
TRPA1 expression (figure 1A,B). Accordingly, Hatano 
et al7 reported recently that the TRPA1 promoter has at 
least six putative NF-κB binding sites; they also showed 
NF-κB to be involved in the induction of TRPA1 in synov-
iocytes. Glucocorticoids8 as well as aurothiomalate9 have 
been shown to inhibit NF-κB activation. Therefore, the 
downregulation of TRPA1 expression by these drugs may 
occur, at least in part, via inhibition of NF-κB.
The present findings, together with previous results,4 5 7 
strongly suggest TRPA1 as a novel factor and drug target 
in arthritis.
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